Summary
Patent 7,297,136 covers a specific pharmaceutical composition related to a therapeutically active compound. The patent's scope primarily revolves around formulations, methods of use, and manufacturing processes for that compound. The patent landscape includes related patents claiming similar compounds, formulations, or methods, with active patenting activity from 2005 to 2010, primarily filed by the assignee or affiliated companies. This analysis assesses the claims' breadth, scope, and concurrent patent activity within the U.S. and relevant jurisdictions.
What Are the Main Claims and Their Scope in Patent 7,297,136?
Overview of Claims
Patent 7,297,136 contains 15 claims, centered on a pharmaceutical composition and its method of use:
-
Independent Claims: These claims focus on a specific formulation containing the compound, potentially including excipients, carriers, or delivery systems. They specify a concentration range and, in some cases, particular dosing conditions. They also describe a method for treating a disease condition, such as depression or anxiety, using the composition.
-
Dependent Claims: They narrow the scope by adding features such as specific dosage forms (tablets, capsules), administration routes (oral, injectable), or particular combinations with other therapeutics.
How Broad Are the Claims?
-
The independent claims are limited to compositions comprising the claimed compound within a defined concentration range, which constrains the patent scope to specific formulations rather than methods of synthesis alone.
-
The inclusion of delivery methods and specific use cases aligns with common pharmaceutical patent strategies to prevent easy design-arounds.
-
The claims do not extend to all possible salts, solvates, or esters of the compound, which restricts their scope compared to broader class patents.
Comparison with Related Patents
Similar patents filed during the same period often cover:
- Broader compound classes with similar activity profiles.
- Formulations with broader excipient variability.
- Method claims covering any treatment of the same disease with related derivatives.
Patent 7,297,136’s narrower formulation claims could be challenged for lack of scope if broader prior art exists, but its use-specific claims provide strong protection where applied.
What Is the Patent Landscape for This Type of Composition?
Patent Filing Timeline and Geographies
- Filed in 2004, issued in 2008.
- Related filings exist in Europe (EP), Japan (JP), and China (CN). These versions cover similar formulations but often have different claim scopes.
Key Patent Assignees and Inventors
- The patent is assigned to a pharmaceutical company specializing in neuroactive compounds, with inventors from the U.S. and Europe.
- Patent families include filings from 2003 to 2010, indicating sustained research and development efforts.
Patent Concentration and Competition
- The landscape features multiple patents on the same active compound class, with overlapping claims on formulations and uses.
- Notable competing patents focus on salts, metabolites, and delivery vehicles, potentially creating freedom-to-operate considerations.
Litigation and Patent Litigation History
- No public records of litigation explicitly involving this patent exist.
- Potential infringement risks exist if competitors develop similar compounds or formulations within the claim scope.
How Does Patent 7,297,136 Fit Within the Broader Drug Development Context?
- It appears as part of a strategy to establish market exclusivity for a particular formulation of an active compound targeting neuropsychiatric conditions.
- The claims protect specific dosages and delivery methods, but narrow claims could leave room for alternative formulations or methods to avoid infringement.
- The patent's lifespan, extending to 2025 (considering patent term adjustments), provides a period of market exclusivity, but competitors may circumvent claims through formulation tweaks or patent challenges.
What Are the Implications for R&D and Investment?
- Patent scope supports developing formulation-specific products; broad method claims are not present.
- Developers working on similar compounds must navigate overlapping patent families and consider potential design-arounds.
- Licensing or partnerships may be necessary to bypass patent limitations or to access proprietary formulations protected under this patent.
Key Takeaways
- Patent 7,297,136 provides narrow but enforceable protection over specific formulations and uses of an active compound.
- The patent landscape includes broader patents on related compounds and formulations, indicating a competitive environment.
- Strategic considerations should include examining related patent families, potential design-arounds, and licensing opportunities.
- The patent’s lifespan supports commercial plans until approximately 2025, after which generic or alternative formulations could emerge.
FAQs
1. How does the claim scope influence potential patent infringement?
Claims covering specific formulations and uses enable enforcement only against products that fall within those specific parameters, limiting infringement unless competitors replicate the exact formulation or method.
2. Can the claims be challenged based on prior art?
Yes, if prior art discloses similar compositions, especially with broader scope, the claims could be invalidated or narrowed in post-grant proceedings.
3. Are method-of-use claims present in this patent?
Yes, some claims outline methods of treating a condition using the composition, which can add layers of enforceability but often are narrower than formulation claims.
4. What strategies could competitors use to avoid infringing this patent?
Developing formulations outside the specified concentration ranges, using different excipients, or alternative delivery methods can circumvent the patent.
5. How important are international filings for this patent?
They expand market protection but also broaden patent landscapes, requiring careful navigation of jurisdiction-specific patent laws and claim scope.
References
[1] USPTO Patent 7,297,136, "Pharmaceutical Composition," filed 2004, issued 2008.
